

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Andrew Cook *et al.*
Title: METHOD DETECTING RHEUMATOID ARTHRITIS EMPLOYING
THE CB10 PEPTIDE FO MAMMALIAN TYPE II COLLAGEN AS
AN ANTIGEN
Prior Appl. No.: 09/623,497, filed 11/20/2000
Appl. No.: Unassigned
Filing Date: February 9, 2004

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop PATENT APPLICATION
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. In accordance with 37 CFR §1.98(d)(1), no copy of the listed documents are being provided because they were either cited by applicants, the USPTO, or an examining authority in a corresponding international application.

The USPTO has waived the requirement under 37 CFR 1.98(a)(2)(i) to submit copies of U.S. patents and U.S. patent application publications when citing and submitting an Information Disclosure Statements in a patent application filed after June 30, 2003 and in an international application that has entered the national stage under 37 USC §371 after June 30, 2003. Accordingly, copies of these types of documents are not being supplied in connection with this application. Reference is being made to Pre-OG Notice from Office of Patent Legal Administration dated July 25, 2003, *Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003.*

The documents listed on the attached PTO/SB/08 were cited as being relevant during the prosecution of the corresponding International application. Copies of the documents are not being provided since copies should have been provided directly by WIPO under an exchange program between the PTO, the EPO and the JPO. A copy of the International Search Report setting forth the portion of each reference considered

relevant by the examiner is attached.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date February 9, 2004

By 

FOLEY & LARDNER
Customer Number: 22428
22428
22428
PATENT TRADEMARK OFFICE
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

Stephen A. Bent
Attorney for Applicant
Registration No. 29,768

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 9, 2004 <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Unassigned
				Filing Date	02/09/2004
				First Named Inventor	Andrew Cook et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	017227-0197
Sheet	1	of	5		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1					
	A2					

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	B1	JP	62-12800	A	JAPAN	01/21/1987		
	B2							
	B3							
	B4							
	B5							

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	C1	Andersson, M. A., et al., "Analysis of Type II Collagen Reactive T Cells in the Mouse" Scand. J. Immunol, Vol. 33, pp. 505-510 (1991)		
	C2	Miyahara, H., et al., "Identification and Characterization of a Major Tolerogenic T-cell Epitope of Type II Collagen that Suppresses Arthritis in B10.RIII Mice", Immunology, Vol. 86, pp. 110-115 (1995)		
	C3	Nabozny, G.H., et al., "Identification of a Cyanogen Bromide Fragment of Porcine Type II Collagen Capable of Modulating Collagen Arthritis in B10.RIII (H2 ¹) Mice" ¹ , Autoimmunity Vol 20, pp. 39-49		
	C4	Kerwar, S.S., et al., "Type II Collagen Induced Arthritis in Rats: Clinical and Immunological Studies", Int. J. Tiss. Reac. Vol. VII(6), pp. 409-429		
	C5	Rowley, M.J., et al., "Epitope Specificity of Antibodies to Type II Collagen in Rheumatoid Arthritis and Systemic Lupus Erythematosus", Rheumatology International, Vol. 12(2), pp. 65-69.		
	C6	Boissier, M.C., et al., "Role De La Conformation Du Collagene Dans L'Immunité Anti-Collagene De Type II Au Cours De La Polyarthrite Rhumatoïde", Revue du Rhumatisme, Vol. 58(1), pp. 19-24 (1991)		
	C7			
	C8			

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 017227/0197		SERIAL NO. Unassigned	
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				APPLICANT Andrew COOK et al.			
				FILING DATE 02/09/2004		GROUP ART UNIT Unassigned	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
		Bornstein, P. and Sage, H. (1980). Structurally distinct collagen Types. Ann. Rev. Biochem. 49:957-1003.					
		Brodsky, B. and Shah, N.K. (1995). The triple-helix motif in proteins FASEB J. 9:1537-1546					
		Buckee, C., Morgan, K., Ayad, S., Collins, I., Clague, R.B., Holt, P.J.L. (1990). Diversity of antibodies to type II collagen in patients with rheumatoid arthritis: detection by binding to -chains and to cyanogen bromide peptides. Brit. J. Rheumatol. 29:254-258					
		Charriere, G., Hartmann, D.J., Vignon, E., Ronziere, M-C., Herbage D., Ville, G. (1988). Antibodies to types I, II, IX, and XI collagen in the serum of patients with rheumatic diseases. Arthritis Rheum. 31:325-332.					
		Choi, E.K.K., Gatenby, P.A., McGill, N.W., Bateman, J.F., Cole, W.G., York, J.R. (1988). Autoantibodies to type II collagen: occurrence in rheumatoid arthritis, other arthritides, autoimmune connective diseases, and chronic inflammatory syndromes. Ann. Rheum. Dis. 47:313-322.					
		Clague, R.B., Shaw, M.J., Holt, P.J.L. (1980). Incidence of serum antibodies to native type I and type II collagen in patients with inflammatory arthritis. Ann. Rheum. Dis. 39:201-206.					
EXAMINER	DATE CONSIDERED						
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 017227/0197	SERIAL NO. Unassigned
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		APPLICANT Andrew COOK et al.	
		FILING DATE 02/09/2004	GROUP ART UNIT Unassigned
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>			
		Collier, D.H., Kerwar, S.S., Garovoy, M.R., Fye, K.H., Stobo, J.D. (1984). Anticollagen antibodies and immune response gene products in rheumatoid arthritis. <i>Arthritis Rheum</i> , 27:1201-1209.	
		Cook, A.D., Rowley, M.J., Stockman, A., Muirden, K.D., Mackay, I.R. (1994). Specificity of antibodies of type II collagen in early rheumatoid arthritis. <i>J. Rheumatol.</i> 21:1186-1191.	
		Cook, A.D., Rowley, M.J., Mackay, I.R., Gough, A., Emery, P. (1996). Antibodies to type II collagen in early rheumatoid arthritis: correlation with disease progression. <i>Arthritis Rheum</i> 39:1720-1727.	
		Courtenay, J.S., Dallman, M.J., Dayan, A.D., Martin, A., Mosedale, B. (1980). Immunization against heterologous type II collagen induces arthritis in mice. <i>Nature</i> 283:666-667.	
		Fujii, K., Tsuji, M., Kitamura, A., Murota, K. (1992). The diagnostic significance of anti-type II collagen antibody assay in rheumatoid arthritis. <i>Int. Orthop.</i> 16:272-276.	
		Gay, S., Gay R.E. and Miller, E.J. (1980). The collagens of the joint. <i>Arthritis Rheum.</i> 23:937-941.	
		Gioud, M., Meghlaoui, A., Costa, O., Monier, J.C. (1982). Antibodies of native type I and II collagens detected by an enzyme linked immunosorbent assay (ELISA) in rheumatoid arthritis and systemic lupus erythematosus. <i>Collagen Rel. Res.</i> 2:557-564.	
		Heinegard, D. and Paulsson, M. (1987). <i>Methods Enzymol.</i> 145:336-363.	
		Hochberg, M.C. (1981). Adult and Juvenile rheumatoid arthritis: current epidemiologic concepts. <i>Epidemiol. Rev.</i> 3:27-44.	
		Miller, E.J. (1985). The structure of fibril-forming collagens. <i>Ann. N.Y. Acad. Sci.</i> 460:1-13.	
		Miller, E.J. and Lunde, L.G. (1973). Isolation and characterization of the cyanogen bromide peptides from the alpha-I(II) chain of bovine and human cartilage collagen. <i>Biochem</i> 12:3153-3159.	
		Miller, E.J. and Rhodes, R.K. (1982). Preparation and characterization of the different types of collagen. <i>Meth. Enzymol.</i> 82:33-64.	
		Morgan, K., Clague, R.B., Collins, I., Ayad, S., Phinn, S.D., Holt, P.J.L. (1987). Incidence of antibodies to native and denature cartilage collagens (types II, IX, and XI) and to type I collagen in rheumatoid arthritis. <i>Ann. Rheum. Dis.</i> 46:902-907.	
		Morgan, K., Clague, R.B., Collins, I., Ayad, S., Phinn, S.D., Holt, P.J.L. (1989). A longitudinal study of anticollagen antibodies in patients with rheumatoid arthritis. <i>Arthritis Rheum.</i> 32:139-145.	

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

017227/0197

SERIAL NO.

Unassigned

INFORMATION DISCLOSURE CITATION

APPLICANT

Andrew COOK et al.

FILING DATE

02/09/2004

GROUP ART UNIT

Unassigned

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Pereira, R.S., Black, C.M., Duance, V.C., Jones, V.E., Jacoby, R.K., Welsh, K.I. (1985) Disappearing collagen antibodies in rheumatoid arthritis. *Lancet ii* :501-502.

Piez, K.A. (1976). Primary structure. In *Biochemistry of collagen*. Ramchandran, G.H. and Reddi, A.N. (eds). Plenum, New York, pp 1-44.

Piez, K.A. (1982). Structure and assembly of the native collagen fibril. *Connect Tissue Res.* 10:25-36.

Rosenberg, A.M., Hunt, D.W.C., Pretty, R.E. (1984). Antibodies to native and denatured type II collagen in children with rheumatic diseases. *J. Rheumatol.* 11:425-431.

Rowley, M.J., Gershwin, M.E., Mackay, I.R. (1988). Collagen antibodies in juvenile arthritis and adult rheumatoid arthritis: differences in levels and type-specificity. *J. Rheumatol.* 15:289-294.

Rowley, M.J., Mackay, I.R., Brand, C.A., Bateman, J.F., Chan, D. (1992). Epitope specificity of antibodies of type II collagen in rheumatoid arthritis and systemic lupus erythematosus. *Rheumatol. Int.* 12:65-69

Scott, P.G. and Veis, A. (1976) The cyanogen bromide peptides of bovine soluble and insoluble collagens. *Connect Tissue Res.* 4:107-116.

Stuart, J.M., Huffstutter, E.H., Townes, A.S., Kang, A.H. (1983). Incidence and specificity of antibodies to types I, II, III, IV and V collagen in rheumatoid arthritis and other rheumatic diseases as measured by ¹²⁵I-radioimmunoassay. *Arthritis Rheum.* 26:832-840.

Steffen, C., Timpl R. (1963). Antigenicity of collagen and its application in the serological investigation of rheumatoid arthritis sera. *Int. Arch. Allergy Appl. Immunol* 22:333-349.

Stockman, A., Rowley, M.J., Emery, P., Muirden, K.D. (1989). Activity of rheumatoid arthritis and levels of collagen antibodies: a prospective study. *Rheumatol. Int.* 8:239-243

Terato, K., Cremer, M.A., Hasty, K.A., Kang, A.H., Hasty, D.L., Townes, A.S. (1985). Physicochemical and immunological studies of the renatured alpha I(II) chains and isolated cyanogen bromide peptides of type II collagen. *Coll. Rel. Res.* 5:469-480.

Terato, K., Shimozuru, Y., Katayama, K., Takemitsu, Y., Yamashita, I., Miyatsu, M., Fujii, K., Sagara, M., Kobayashi, S., Goto, M., Nishioka, K., Miyatsaka, N., Nagai, Y. (1990). Specificity of antibodies of type II collagen in rheumatoid arthritis. *Arthritis Rheum* 33:1493-1500.

Trentham, D.E. Townes, A.S., Kang, A.H. (1977). Autoimmunity to type II collagen: an experimental model of arthritis. *J. Exp. Med.* 146:857-868.

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 017227/0197	SERIAL NO. Unassigned
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		APPLICANT Andrew COOK et al.	
		FILING DATE 02/09/2004	GROUP ART UNIT Unassigned
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>			
		Trentham, D.E. Kammer, G.M., McCune, W.J., David, J.R. (1981). Autoimmunity to collagen. A shared feature of psoriatic and rheumatoid arthritis. Arthritis Rheum. 24:1363-1369.	
		Werkmeister, J.A., Ramshaw, J.A. M (1991). Multiple antigenic determinants on type III collagen. Biochem J. 274:895-898.	